Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (January 2015)
28 slides from Matinas Biopharma's investor presentation, Jan 30, 2015
Slide 1: Corporate Presentation January 2015
OTCQB: MTNB CORPORATE PRESENTATION January 2015 www.MatinasBioPharma.com A clinical - stage biopharmaceutical company focused on the development of lipid - based prescription therapeutics for the treatment of cardiovascular and metabolic conditions and infectious diseases 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other st
Slide 3: Investment Highlights
Investment Highlights • Unique and differentiated expertise in lipidomics , lipid chemistry and lipid - based delivery • Phase 2a and Phase 3 clinical development programs expected to commence in 2015 • Novel technology platform with broad application expected to drive a robust pipeline in high - va
Slide 4: Our Lipid-based Therapy Approach
Our Lipid - based Therapy Approach Lipid - Based Therapies Lipids as Pharmaceutically Active Compounds ▪ MAT9001 • Severe hypertriglyceridemia • Other dyslipidemia ▪ MAT8800 • Fatty Liver Disease Lipids as “ Nano - Particle” Delivery Vehicles ▪ MAT2203 – C - Amphotericin B • Broad Spectrum Fungicida
Slide 5: Matinas BioPharma Pipeline
Matinas BioPharma Pipeline Discovery IND Preparation Early Clinical Development Phase 3 Development 5 MAT9001 MAT2203 MAT2501 MAT8800 Severe Hypertriglyceridemia Fungal Infections Gram - Negative Bacterial Infections Fatty Liver Disease Discovery Program
Slide 6: MAT9001: A Next Generation Prescription-only Omega Fatty Acid Medication
6 MAT9001 A Next Generation Prescription - only Omega - 3 Fatty Acid Medication
Slide 7: Not All Omega-3s are the Same
Not All Omega - 3s are the Same MTNB focus on UNIQUE OMEGA - 3S 7 COMMON OMEGA - 3S EPA Not all Rx Omega - 3s are the same : Repurposed drugs DHA LOVAZA (EPA and DHA) EPANOVA (EPA and DHA) VASCEPA (Pure EPA) High DHA Low DHA ALA ETA HPA DPA SDA K ey Differentiation Driver for MTNB DHA is associated
Slide 8: MAT9001 – Uniquely Engineered Omega Composition
MAT9001 – Uniquely Engineered Omega - 3 Composition x Severe Hypertriglyceridemia (≥500mg/dL) x Highest potency x Unique Mechanism of Action 8 EPA SPECIFICALLY DESIGNED TO TREAT DYSLIPIDEMIA DPA
Slide 9: High Triglycerides: Risks and Patient Numbers
HIGH triglycerides Pancreatitis Cardiovascular Disease Type 2 Diabetes Fatty Liver Disease HIGH risk: 9 HIGH number of patients with high triglycerides ~4M ~65M (TG≥150mg/dl) (TG≥500mg/dl)
Slide 10: Docosapentaenoic Acid (DPA) Differentiation
Docosapentaenoic Acid (DPA) Differentiation 10 -60% -50% -40% -30% -20% -10% 0% 50 200 400 1000 EPA 200 mg/kg EPA 400 mg/kg EPA 1000 mg/kg DPA 50 mg/kg TG Percent reduction from baseline in “Fatty Zucker ” rats after 1 week of dosing (n=8 per treatment group). Source: Matinas BioPharma research; unp
Slide 11: MAT9001 – Program Achievements
MAT9001 – Program Achievements x Promising results with DPA in pre - clinical studies x Proprietary process for high purity DPA manufacturing, at GMP 10+kg scale x Development of proprietary soft - gel formulation x Formation of prominent Scientific Advisory Board x Filed MAT9001 IND with FDA Q4 201
Slide 12: MAT9001 – Development Overview
MAT9001 – Development Overview Discovery IND Preparation Early Clinical Development Phase 3 Development MAT9001 12 Next Steps: • Comparative PK/PD crossover study ongoing in Canada – ~50 pts • Protocol responses to FDA (comparative PK and animal tox ) • Conduct comparative PK and animal tox studies
Slide 13: MAT2203: Amphotericin B in Lipid-Crystal Nano-Particle Cochleate Formulation
13 MAT2203 Amphotericin B Delivered in a Lipid - Crystal Nano - Particle Cochleate Formulation
Slide 14: Cochleate Targeted Nano-particle Delivery Mitigates Limitations of Amphotericin B
Cochleate Targeted Nano - particle Delivery Mitigates the Limitations of Amphotericin B 14 50 - 500 nm * Phosphatidylserine PS* Bilayer Calcium Drug 1. Reduces toxicity by containing drug inside particle 2. Size and surface features facilitate targeted delivery 3. Potential for oral administration H
Slide 15: Cochleate Technology Offers Significant Clinical Improvement Potential
Cochleate Technology Offers S ignificant C linical I mprovement P otential Multi - Organ Protection • Cochleates act as a shield for the body from otherwise toxic medicinal compounds Targeted Delivery • Cochleates are carried directly to infection sites Oral Administration • Efficacy demonstrated in
Slide 16: Selective Cellular Uptake of Cochleates
Selective Cellular Uptake of Cochleates 16 Cochleates are taken up by cells like macrophages… …or by the fungus itself Cochleate interacting with a macrophage in cell culture Florescent labeled cochleates in the fungal hyphae
Slide 17: Efficacy with Reduced Toxicity
Efficacy with Reduced Toxicity 17 Comparative Amphotericin B Study In Mouse Fungal Model Survival % Days 0% 20% 40% 60% 80% 100% Control Existing AmB (IV, 1mg/kg) Existing AmB (IV, 2mg/kg) AmB Cochleates (Oral, 0.5 mg/kg ) ▪ Candidiasis mouse model at PHRI ▪ Oral delivery of encochleated Amphoterici
Slide 18: Invasive Fungal Infections: Significant Clinical Need
Invasive Fungal Infections x Cryptococcal Meningoencephalitis x Aspergillosis Significant Clinical Need for Fungicidal Agents Hematological Malignancies x Leukemias • ALL • AML Stem Cell Transplants x Autologous x Allogeneic Solid Organ Transplants x Kidney x Liver x Other Approximately 150,000 case
Slide 19: Cochleate Technology Has Led to Several NIH Collaborations
Scientific Merit of Cochleate Technology and Clinical Unmet Need has Led to Several NIH Collaborations • NIH SBIR grants and research contracts towards encochleated Amphotericin B research • NIH SBIR grants and research contracts toward encochleated Aminoglycoside antibiotics research – Amikacin – C
Slide 20: Cochleate Nanoparticle Delivery Has Broad Utility
Cochleate Nanoparticle Delivery has Broad Utility with Potential for Orphan Drug Applications Collaborations In - Vitro Animal POC IND - Prep Human Studies Amphotericin B NIH / PHRI Amikacin NIH Vaccines Ibuprofen Atovaquone NIH Capreomycin NIH Meropenem NIH Curcumin Omega - 3 FA 20
Slide 21: MAT2203 – Recent Significant Advancements
MAT2203 – Recent Significant Advancements x Completed c ryptococcal meningitis mouse studies at NIH with C - Amphotericin B x Increasing C - Amphotericin B scale to ~800 doses/batch x Preparing for C - Amphotericin B Phase 2a efficacy trial at NIH – refractory mucocutaneous candidiasis patients 21
Slide 22: MAT2203 – Development Overview
MAT2203 – Development Overview Discovery IND Preparation Early Clinical Development Phase 3 Development MAT2203 22 Next Steps: ▪ Single - Dose Phase 1 study completed ▪ Patient treatment protocols under development in collaboration with NIH/NIAID ▪ Commence Phase 2a study in 1H 2015
Slide 23: MAT8800 Fatty Liver Disease Discovery Program
23 MAT8800 Fatty Liver Disease Discovery Program
Slide 24: MAT8800 – Development Overview
MAT8800 – Development Overview MAT8800 – Proprietary Omega - 3 Discovery Program Treating Fatty Liver Disease NAFLD NASH • Common: 12% of U.S. population • A leading cause of cirrhosis • NO APPROVED TREATMENT OPTION 24 Discovery IND Preparation Early Clinical Development Phase 3 Development MAT8800
Slide 25: Experienced Management Team and Board
Experienced Management Team and Board Roelof Rongen – President and CEO, Director George Bobotas , PhD – Chief Scientific Officer Jerome Jabbour , JD – Chief Business Officer & General Counsel Abdel Fawzy , PhD – EVP Pharmaceutical & Supply Chain Dev. Gary Gaglione, CPA – VP Finance, Acting CFO Herb
Slide 26: World Class Scientific Advisory Board
Dyslipidemia & Cardiovascular Disease Christie M. Ballantyne, MD, PhD, FACC, FNLA – Baylor College of Medicine , Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center, Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital Kevin Maki, PhD,
Slide 27: MTNB Represents a Compelling Investment Opportunity
MTNB Represents a Compelling I nvestment O pportunity x Unique and differentiated expertise in lipidomics , lipid chemistry and lipid - based delivery x Phase 2a and Phase 3 clinical development programs expected to commence in 2015 x Novel technology platform with broad application expected to driv
Slide 28: www.MatinasBioPharma.com
OTCQB: MTNB CORPORATE PRESENTATION January 2015 www.MatinasBioPharma.com A clinical - stage biopharmaceutical company focused on the development of lipid - based prescription therapeutics for the treatment of cardiovascular and metabolic conditions and infectious diseases 28
Matinas BioPharma Holdings — Investor Presentation (January 2015) on 6ix